New CBO findings on brand drug price increases “drive home the urgent need to pass robust drug pricing reforms," U.S. Senate Finance Committee Chair Ron Wyden (D-Ore.) said this week.

Democrats Weigh Passing Build Back Better Act—Possibly Including Drug Pricing Reforms—in “Chunks”

U.S. Senate Finance Committee Chair Ron Wyden (D-Ore.) said this week that new Congressional Budget Office (CBO) findings on brand drug price increases “drives home the urgent need to pass robust drug pricing reforms.”

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
×

*Sign up for news summaries and alerts from 340B Report